You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2024

Indonesia Imposes Stringent Requirements on Electronic Cigarettes

Subscribe to Updates

Government Regulation No. 28 of 2024 (“GR No. 28”) was issued on July 26, 2024, to implement Law No. 17 of 2023 on Health (the “Omnibus Health Law”). GR No. 28 contains extensive provisions on tobacco products and electronic cigarettes in an effort to reduce the health risks associated with addictive substances, decrease the prevalence of smokers, and prevent the initiation of smoking among beginners in Indonesia.

The Indonesian FDA (known as “BPOM”) is working to implement the relevant provisions in GR No. 28 and has subsequently issued a draft regulation on the control and distribution of tobacco products and electronic cigarettes. This draft regulation is set to replace current BPOM Regulation No. 41 of 2013, which only covered tobacco products. The new draft regulation, however, also incorporates rules on electronic cigarettes.

This article outlines some of the measures on electronic cigarettes contained in GR No. 28 and the draft implementing regulation, focusing particularly on testing and reporting requirements, sale and pack size requirements, and labeling and advertising requirements.

Testing and Reporting

The draft regulation requires that each variant of electronic cigarettes produced or imported be tested for nicotine content. These tests must be conducted in an accredited laboratory, and the results must be reported to BPOM.

The use of additive materials is prohibited unless they have been proven safe for public health. To enforce this, electronic cigarettes must be tested for the presence of prohibited additives before they are distributed. Additionally, a verification of the content of prohibited additives must be conducted during the distribution period, with the testing and verification being carried out in different laboratories. The results of both tests (i.e., the pre-distribution test and the subsequent verification) must be reported to BPOM.

Sale and Pack Size

GR No. 28 prohibits the sale of electronic cigarettes:

  • Via self-service machines;
  • To individuals under the age of 21 (an increase over the previous minimum age of 18 years old) or to pregnant women;
  • In locations near entrance and exit doors or in high-traffic areas;
  • Within 200 meters of children’s educational facilities or playgrounds; and
  • Through web services, commercial electronic applications, or social media platforms without age verification.

GR No. 28 also establishes pack size requirements for electronic cigarettes. For closed-system or single-use cartridge electronic cigarettes, the liquid nicotine content must not exceed 2 mL per cartridge, and each package cannot contain more than two cartridges. For open-system or refillable electronic cigarettes, liquid nicotine must be sold in 10-milliliter or 20-milliliter containers. For solid electronic cigarettes, there must be 20 sticks per pack.

Labeling

Electronic cigarette labels are required to display health warnings in both text and image format, providing educational information about the risks of smoking. These health warnings must be printed on the package surface as an integral part of the packaging. There are five different required warnings for each variant of electronic cigarette. Each of the five warnings must be equally displayed on all of the electronic cigarette packs for each variant.

The health warning text and images must be displayed on all sizes of electronic cigarette packages. Each package must show one type of health warning, which cannot be obscured by anything else. The warning must meet the following criteria:

  • The warning must be displayed on the top portion of the package (horizontal orientation), on both the front and back, covering 50% of the surface area;
  • The packaging must include the word “warning” in yellow text that stands out clearly on a black background;
  • The image must be printed in color; and
  • The font must be Arial Bold, proportional to the package size, with yellow text on a black background.

The draft regulation also requires electronic cigarette labels to include the following information:

  • A statement that the product contains nicotine;
  • A statement that the product is prohibited from being sold or provided to individuals under the age of 21 or to pregnant women; and
  • The production code; date, month, and year of production; and the name and address of the manufacturer.

The label must not contain any misleading information or sign or any promotional wording.

Advertising

GR No. 28 stipulates extensive advertising requirements for electronic cigarettes. Advertising on digital-based social media platforms is prohibited. GR No. 28 also specifies requirements for advertisements placed on websites and commercial electronic applications. requirements for advertisements at point-of-sale locations and via outdoor media, print media, and broadcasting media.

Advertisements on websites or commercial electronic applications:

  • Must include a health warning and a statement prohibiting the sale or provision of electronic cigarettes to individuals under the age of 21 and to pregnant women;
  • Must not illustrate or suggest that using electronic cigarettes offers health benefits;
  • Must not use misleading words or phrases or encourage the consumption of electronic cigarettes,
  • Must not depict the use or display of electronic cigarettes or any references that could be associated with the brand;
  • Must not feature children, teenagers, or pregnant women in any pictures or text;
  • Must not target children, teenagers, or pregnant women;
  • Must not use cartoons or animation as advertising characters;
  • Must not contradict public norms;
  • Must implement age verification to limit access to those 21 years old and above.

Conclusion

Businesses operating in the electronic cigarette industry in Indonesia need to stay vigilant and proactive in response to these new regulatory requirements. Compliance will not only require adjustments in production, packaging, and marketing strategies but also proactive due diligence to avoid potential legal repercussions. Companies should consider conducting comprehensive audits of their current practices and seek legal counsel to ensure full compliance with the evolving regulatory landscape. By doing so, they can better navigate the complexities of these stringent regulations and mitigate risks that could impact their market presence and operational continuity.

Related Professionals

Practices

Regulatory Affairs

Location

RELATED INSIGHTS​ 

August 8, 2025
In response to persistent challenges in food safety management and recent high-profile incidents involving counterfeit supplemented foods, infant formula, and health supplements, the Ministry of Health of Vietnam is initiating comprehensive regulatory reforms. These reforms include proposed amendments to the Law on Food Safety and its implementing Decree No. 15/2018/ND-CP (Decree 15), introducing significant changes to the registration procedures for food products, especially supplemented food products and health supplements. While awaiting public consultation and approval of the amended Law on Food Safety, the Ministry of Health is developing an interim mechanism, which includes a draft decree to replace Decree 15 and a draft resolution to address urgent issues until the amended law becomes effective, expected in July 2026. To align with the new Law on Quality of Products and Goods, the draft resolution stipulates that the declaration and registration of food products will follow the following procedures: Declaration of applied standards for food products, which is currently known as the “self-declaration” procedure, applies to processed packaged foods, food additives, food processing aids, containers or utensils that come into direct contact with food, packaging materials in direct contact with food, and micronutrients. Granting of circulation numbers, which is the current “registration of product declaration” procedure, applies to specific categories of food including health supplements, medical nutrition foods, special dietary foods, nutritional products for children up to 36 months, and, especially, supplemented foods, which are currently subject to self-declaration but will be shifted to this registration procedure. In addition, the following new procedure is introduced in the draft decree: Registration of declaration of conformity, which applies to the same product category as in “declaration of applied standards” above, but is for products that are already subject to technical regulations covering both safety indicators and quality indicators. Changes to the Food Product
Read More
July 15, 2025
On July 1, 2025, Vietnam’s Ministry of Health issued Circular No. 30/2025/TT-BYT providing updated guidance on the application of drug quality standards, testing of drugs and pharmaceutical ingredients, and procedures for the recall and handling of noncompliant drugs (Circular 30). Circular 30 officially came into effect on the same day and replaces Circular No. 11/2018/TT-BYT and its amendments. Key highlights of Circular 30 are presented below. Drug and Pharmaceutical Ingredient Quality Standards Circular 30 maintains consistency with previous regulations regarding the selection of an applicable quality specification. Pharmaceutical businesses and drug preparation establishments may still choose to apply standards from the Vietnamese Pharmacopoeia, reference pharmacopoeias (including the United States Pharmacopoeia, the European Pharmacopoeia, the British Pharmacopoeia, the Japanese Pharmacopoeia, and the International Pharmacopoeia), or an in-house specification. Priority is given to the Vietnamese Pharmacopoeia and reference pharmacopoeias, encompassing quality indicators, quality levels, and testing methods. If alternative pharmacopoeias or in-house specifications are used, they must meet the requirements outlined in the corresponding monographs of the Vietnamese or reference pharmacopoeias. At the time of registration, the quality standards of drugs and pharmaceutical ingredients must comply with either the current version of the pharmacopoeia or a previous version of the pharmacopoeia that is no more than two years older than the current version. The requirement for updating quality specifications in line with the quality under the corresponding pharmacopoeia also applies to products that have already been granted marketing authorization. Testing Drugs and Pharmaceutical Ingredients in Quality Management Similar to the regulations under the previous circular, if pharmaceutical businesses disagree with the sample testing results, they may, within five working days of receiving the test report, request that the state quality inspection authority designate an alternative testing facility. The testing period for establishments listed as foreign drug manufacturers with quality violations remains
Read More
July 14, 2025
Life sciences specialists from Tilleke & Gibbins have updated the firm’s guide to pharmaceutical data exclusivity regulations and practices in Southeast Asia. This guide contains quick-reference information on the availability of data exclusivity protections and limitations in Cambodia, Indonesia, Laos, Malaysia, Myanmar, Thailand, and Vietnam. Developing and launching a new drug on a commercial scale requires an enormous amount of time and investment in research and development (R&D), including pre-clinical testing and clinical trials. When considering the aggregate amount of drug development costs, it is important to recognize that this includes not only the investment in developing new drugs that get approved by a government food and drug regulator and are successfully brought to market, but also the R&D expenditures on a large number of potential pharmaceutical compounds and products that never actually make it to market. In particular, considerable investment is required in order to conduct and produce clinical trial data—to prove safety, efficacy and effectiveness of a new drug—that would warrant marketing approval by the regulatory authority. Such data is proprietary in nature and highly valuable for a research-based pharmaceutical company that develops an original drug. On the other hand, patent law typically confers generic drug manufacturers with the ability to engage in various preparatory activities with a view to obtaining marketing approval for a generic product before the patent for the original drug expires (commonly known as a “Bolar provision”). Since a generic drug maker may submit an application for marketing approval of a generic product before the relevant patent expires, the extent to which the drug originator’s data submitted to the regulatory authority is protected—or in other words, the extent to which the generic company may rely on the drug originator’s previously filed data, which underpins the safety and efficacy of the drug, to support
Read More
July 9, 2025
On June 16, 2025, the National Assembly of Vietnam adopted Law No. 75/2025/QH15 amending and supplementing a number of articles of the 2012 Advertising Law, with an effective date of January 1, 2026. The amended Advertising Law was enacted to further refine the legal framework for advertising activities in the modern era. Online Advertising Under the amended Advertising Law, “online advertising” is defined to encompass not only advertising on electronic newspapers and electronic information pages (as provided under the 2012 Advertising Law) but also advertising on other electronic venues, including social media, online applications, and digital platforms with internet connection. The amended Advertising Law also imposes new requirements for online advertising, including: Identification signs: Advertisements must have clear identifiable signs in numbers, letters, symbols, images, or sounds to distinguish them from non-advertising content. Control features: For advertisements not in fixed areas, there must be easily recognizable features and icons that allow recipients to turn off the advertisement, notify the service provider of violating advertising content, and refuse to view inappropriate advertising content. Linked content: Content in the links embedded in advertisements must comply with the law. Advertising service providers and publishers must have measures to check and monitor the linked content. Advertising on social media: Organizations and enterprises providing social media services must offer users features to distinguish advertising content from other content. Signage for sponsored content: When advertising, users of social media services must use signs to differentiate advertising or sponsored content from other content they provide. In response to the above requirements for online advertising, the amended Advertising Law sets out obligations of advertisers, advertising service providers, advertising publishers, and advertising conveyors in relation to online advertising. Among these, it is notably the responsibility of individuals and organizations engaging in online advertising to prevent and remove violating
Read More